Targeting integrins in hepatocellular carcinoma

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 4, 2011, Pages 421-437

  Wu, Yanhua ^a   Qiao, Xiaojing ^a   Qiao, Shouyi ^a   Yu, Long ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Angiogenesis; extracellular matrix; hepatocellular carcinoma; integrin

Indexed keywords

ALPHA6 INTEGRIN; ANT 161; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; CETUXIMAB; CILENGITIDE; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; E 7820; EMD 525797; ETARACIZUMAB; FC 336; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMGN 388; INTEGRIN; INTETUMUMAB; IRINOTECAN; PF 04605412; PREDNISONE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 3; VERY LATE ACTIVATION ANTIGEN 5; VERY LATE ACTIVATION ANTIGEN 6; VOLOCIXIMAB; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; LIVER CELL CARCINOMA; MELANOMA; METASTASIS INHIBITION; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; INTEGRINS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 79952674668     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.555402     Document Type: Review

References (152)

1. Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
3. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25
4. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem 2000;275:21785-8 (Pubitemid 30621742)
5. Hughes PE, Pfaff M. Integrin affinity modulation. Trends Cell Biol 1998;8:359-64 (Pubitemid 28398427)
6. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998;91:2645-57 (Pubitemid 28227512)
7. Li R, Mitra N, Gratkowski H, et al. Activation of integrin alphaIIbbeta3 by modulation of transmembrane helix associations. Science 2003;300:795-8 (Pubitemid 36532114)
8. Carman CV, Springer TA. Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr Opin Cell Biol 2003;15:547-56 (Pubitemid 37176963)
9. Xiong JP, Stehle T, Diefenbach B, et al. Crystal structure of the extracellular segment of integrin alphaVbeta3. Science 2001;294:339-45 (Pubitemid 32963395)
10. Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin alphaVbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002;296:151-5 (Pubitemid 34280076)
11. Coller BS. Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol 1986;103:451-6 (Pubitemid 16055041)
12. Beer JH, Springer KT, Coller BS. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood 1992;79:117-28
13. DeMali KA, Wennerberg K, Burridge K. Integrin signaling to the actin cytoskeleton. Curr Opin Cell Biol 2003;15:572-82 (Pubitemid 37176966)
14. Price LS, Leng J, Schwartz MA, Bokoch GM. Activation of Rac and Cdc42 by integrins mediates cell spreading. Mol Biol Cell 1998;9:1863-71 (Pubitemid 28337528)
15. Ren XD, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J 1999;18:578-85 (Pubitemid 29057242)
16. del Pozo MA, Price LS, Alderson NB, et al. Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J 2000;19:2008-14 (Pubitemid 30237576)
17. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998;10:220-31 (Pubitemid 28174764)
18. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998;140:1255-63 (Pubitemid 28128883)
19. Soldi R, Mitola S, Strasly M, et al. Role of alphaVbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999;18:882-92 (Pubitemid 29082268)
20. De S, Razorenova O, McCabe NP, et al. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA 2005;102:7589-94 (Pubitemid 40741015)
21. Short SM, Boyer JL, Juliano RL. Integrins regulate the linkage between upstream and downstream events in G protein-coupled receptor signaling to mitogen-activated protein kinase. J Biol Chem 2000;275:12970-7 (Pubitemid 30241455)
22. Moro L, Venturino M, Bozzo C, et al. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J 1998;17:6622-32 (Pubitemid 28521796)
23. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-26 (Pubitemid 39336275)
24. Zhou GF, Ye F, Cao LH, Zha XL. Over expression of integrin alpha 5 beta 1 in human hepatocellular carcinoma cell line suppresses cell proliferation in vitro and tumorigenicity in nude mice. Mol Cell Biochem 2000;207:49-55 (Pubitemid 30399368)
25. Palmer EL, Ruegg C, Ferrando R, et al. Sequence and tissue distribution of the integrin alpha9 subunit, a novel partner of beta1 that is widely distributed in epithelia and muscle. J Cell Biol 1993;123:1289-97 (Pubitemid 23352436)
26. Volpes R, van den Oord JJ, Desmet VJ. Integrins as differential cell lineage markers of primary liver tumors. Am J Pathol 1993;142:1483-92 (Pubitemid 24058135)
27. Torimura T, Ueno T, Kin M, et al. Coordinated expression of integrin alpha6beta1 and laminin in hepatocellular carcinoma. Hum Pathol 1997;28:1131-8 (Pubitemid 27446598)
28. Clement B, Rescan PY, Baffet G, et al. Hepatocytes may produce laminin infibrotic liver and in primary culture. Hepatology 1988;8:794-803
29. Le Bail B, Faouzi S, Boussarie L, et al. Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver. J Pathol 1997;181:330-7 (Pubitemid 27156848)
30. Ozaki I, Yamamoto K, Mizuta T, et al. Differential expression of laminin receptors in human hepatocellular carcinoma. Gut 1998;43:837-42 (Pubitemid 28539665)
31. Masumoto A, Arao S, Otsuki M. Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells. Hepatology 1999;29:68-74 (Pubitemid 29023988)
32. Giannelli G, Fransvea E, Bergamini C, et al. Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res 2003;9:3684-91 (Pubitemid 37169236)
33. Bergamini C, Sgarra C, Trerotoli P, et al. Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology 2007;46:1801-9
34. Giancotti FG, Ruoslahti E. Elevated levels of the alpha5beta1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990;60:849-59
35. Su JM, Gui L, Zhou YP, Zha XL. Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance. World J Gastroenterol 2002;8:613-18 (Pubitemid 34918651)
36. Yao M, Zhou XD, Zha XL, et al. Expression of the integrin alpha5 subunit and its mediated cell adhesion in hepatocellular carcinoma. J Cancer Res Clin Oncol 1997;123:435-40 (Pubitemid 27356304)
37. Zhao J, Zhai W, Zhang Y. Expression of integrin alpha5, beta1 subunit and fibronectin mRNAs in human hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi 1998;27:94-8
38. Wu Y, Zuo J, Ji G, et al. Proapoptotic function of integrin beta3 in human hepatocellular carcinoma cells. Clin Cancer Res 2009;15:60-9
39. Jaskiewicz K, Chasen MR. Differential expression of transforming growth factor alpha, adhesions molecules and integrins in primary, metastatic liver tumors and in liver cirrhosis. Anticancer Res 1995;15:559-62, 43
40. Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001;98:15089-94 (Pubitemid 34013974)
41. Varner JA, Emerson DA, Juliano RL. Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 1995;6:725-40
42. Fang Z, Fu Y, Liang Y, et al. Increased expression of integrin beta1 subunit enhances p21WAF1/Cip1 transcription through the Sp1 sites and p300-mediated histone acetylation in human hepatocellular carcinoma cells. J Cell Biochem 2007;101:654-64 (Pubitemid 46698850)
43. Liang YL, Fu Y, Chen SG, et al. Integrin beta1 subunit overexpressed in the SMMC-7721 cells regulates the promoter activity of p21CIP1 and enhances its transcription. FEBS Lett 2004;558:107-13 (Pubitemid 38167419)
44. Fang Z, Yao W, Fu Y, et al. Increased integrin alpha5beta1 heterodimer formation and reduced c-Jun expression are involved in integrin beta1 overexpression-mediated cell growth arrest. J Cell Biochem 2010;109:383-95
45. Carloni V, Romanelli RG, Mercurio AM, et al. Knockout of alpha6beta1-integrin expression reverses the transformed phenotype of hepatocarcinoma cells. Gastroenterology 1998;115:433-42 (Pubitemid 28363436)
46. Kikkawa Y, Sudo R, Kon J, et al. Laminin alpha5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule. Exp Cell Res 2008;314:2579-90
47. Giannelli G, Bergamini C, Fransvea E, et al. Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 2001;81:613-27 (Pubitemid 32298807)
48. Tang J, Wu YM, Zhao P, et al. betaig-h3 interacts with alpha3beta1 integrin to promote adhesion and migration of human hepatoma cells. Exp Biol Med 2009;234:35-9
49. Tian B, Li Y, Ji XN, et al. Basement membrane proteins play an active role in the invasive process of human hepatocellular carcinoma cells with high metastasis potential. J Cancer Res Clin Oncol 2005;131:80-6 (Pubitemid 40192932)
50. Honma N, Genda T, Matsuda Y, et al. MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. Lab Invest 2006;86:687-96 (Pubitemid 43901666)
51. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010;11:97-105
52. Zhang H, Ozaki I, Mizuta T, et al. Transforming growth factor-beta1-induced apoptosis is blocked by beta1-integrin-mediated mitogen-activated protein kinase activation in human hepatoma cells. Cancer Sci 2004;95:878-86 (Pubitemid 40045522)
53. Kim HP, Kim TY, Lee MS, et al. TGF-beta1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27Kip1 CDK inhibitor in hepatoma cells replated on fibronectin. Biochim Biophys Acta 2005;1743:151-61
54. Cai T, Lei QY, Wang LY, Zha XL. TGF-beta1 modulated the expression of alpha5beta1 integrin and integrin-mediated signaling in human hepatocarcinoma cells. Biochem Biophys Res Commun 2000;274:519-25 (Pubitemid 30614350)
55. Giannelli G, Fransvea E, Marinosci F, et al. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 2002;161:183-93 (Pubitemid 34760784)
56. Yang C, Zeisberg M, Lively JC, et al. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res 2003;63:8312-17 (Pubitemid 37549483)
57. Giannelli G, Bergamini C, Fransvea E, et al. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellularcarcinoma. Gastroenterology 2005;129:1375-83 (Pubitemid 41597379)
58. Fransvea E, Mazzocca A, Antonaci S, Giannelli G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 2009;49:839-50
59. Matsuo M, Sakurai H, Ueno Y, et al. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. Cancer Sci 2006;97:155-62 (Pubitemid 43379484)
60. Wang Z, Wang M, Carr BI. Integrin alpha5-induced EGFR activation by prothrombin triggers hepatocyte apoptosis via the JNK signaling pathway. J Cell Physiol 2008;216:551-7 (Pubitemid 351898484)
61. Torimura T, Ueno T, Kin M, et al. Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins. Hepatology 2001;34:62-71 (Pubitemid 32591484)
62. Choi S, Lee SA, Kwak TK, et al. Cooperation between integrin alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood 2009;113:1845-55
63. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010;9:804-20
64. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alphavbeta3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22
65. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000;6:3056-61 (Pubitemid 30637728)
66. Mulgrew K, Kinneer K, Yao XT, et al. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, AbegrinTM. Mol Cancer Ther 2006;5:3122-9 (Pubitemid 46092054)
67. Landen CN, Kim TJ, Lin YG, et al. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 2008;10:1259-67
68. Delbaldo C, Raymond E, Vera K, et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 2008;26:35-43
69. McNeel DG, Eickhoff J, Lee FT, et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 2005;11:7851-60 (Pubitemid 41611630)
70. Trikha M, Zhou Z, Nemeth JA, et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004;110:326-35 (Pubitemid 38649882)
71. Chen Q, Manning CD, Millar H, et al. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis 2008;25:139-48
72. Martin PL, Jiao Q, Cornacoff J, et al. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res 2005;11:6959-65 (Pubitemid 41428754)
73. Ning S, Nemeth JA, Hanson RL, et al. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther 2008;7:1569-78
74. Mullamitha SA, Ton NC, Parker GJ, et al. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 2007;13:2128-35 (Pubitemid 46649882)
75. Chen Q, Millar HJ, McCabe FL, et al. alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin Cancer Res 2007;13:3689-95 (Pubitemid 46955133)
76. Vater CA, Manning C, Millar H, et al. Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models. 20th EORTC-NCI-AACR symposium [abstract 529]. Mol Targets Cancer Ther EJC Suppl 2008;6(12):167
77. A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors. Bethesda, MD: clinicaltrials.gov, 2008. Available from: [Last accessed 26 January 2011]
78. Mitjans F, Meyer T, Fittschen C, et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 2000;87:716-23 (Pubitemid 30620415)
79. A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer. Bethesda, MD: clinicaltrials.gov, 2009. Available from: .gov/ct2/show/NCT00958477 [Last accessed 26 January 2011]
80. EMD 525797 in Colorectal & Ovarian Cancer Patients With Liver Metastases. Bethesda, MD: clinicaltrials.gov, 2009. Available from: [Last accessed 26 January 2011]
81. EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wildtype Metastatic Colorectal Cancer. Bethesda, MD: clinicaltrials.gov, 2009. Available from: [Last accessed 26 January 2011]
82. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-62 (Pubitemid 30660012)
83. Yazji S, Bukowski R, Kondagunta V, Figlin R. Final results from phase II study of volociximab, an alpha5beta1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25:abstract 5094
84. Ramakrishnan V, Bhaskar V, Law DA, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as anovel anti-angiogenic agent. J Exp Ther Oncol 2006;5:273-86 (Pubitemid 44497002)
85. Ricart AD, Tolcher AW, Liu G, et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a Phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008;14:7924-9
86. Barton J. A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2008. J Clin Oncol 2008;26(20 Suppl 15S):9051
87. A safety study of a monoclonal antibody against A5B1 integrin in solid tumors. Bethesda, MD: clinicaltrials.gov, 2009. Available from: [Last accessed 26 January 2011]
88. Erdreich-Epstein A, Tran LB, Cox OT, et al. Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways. Blood 2005;105:4353-61 (Pubitemid 40720781)
89. Smith JW, Ruggeri ZM, Kunicki TJ, Cheresh DA. Interaction of integrins alphavbeta3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J Biol Chem 1990;265:12267-1271
90. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25:1651-7 (Pubitemid 46797943)
91. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alphav integrin antagonist. Neurosurgery 2001;48:151-7 (Pubitemid 32039837)
92. Yamada S, Bu XY, Khankaldyyan V, et al. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 2006;59:1304-12; discussion 1312 (Pubitemid 44949775)
93. Burke PA, DeNardo SJ, Miers LA, et al. Cilengitide targeting of alphavbeta3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-72 (Pubitemid 34827281)
94. Beekman KW, Colevas AD, Cooney K, et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 2006;4:299-302 (Pubitemid 43779890)
95. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008;26:919-24 (Pubitemid 351398085)
96. Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003;39:917-26 (Pubitemid 36428623)
97. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610-17
98. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). ASCO Annual Meeting Proceedings 2007. J Clin Oncol 2007;25(Part I 18S):abstract 2000
99. Khalili P, Arakelian A, Chen G, et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006;5:2271-80 (Pubitemid 44530464)
100. Cianfrocca ME, Kimmel KA, Gallo J, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006;94:1621-6 (Pubitemid 43924924)
101. Funahashi Y, Sugi NH, Semba T, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res 2002;62:6116-23 (Pubitemid 35244460)
102. Semba T, Funahashi Y, Ono N, et al. An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. Clin Cancer Res 2004;10(4):1430-8 (Pubitemid 38365238)
103. Mita MM, Mita AC, Ricart A, et al. Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006. J Clin Oncol 2006;24(18S):abstract 3048
104. A Phase II study of the safety and efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors. Bethesda, MD: clinicaltrials.gov, 2006. Available from: [Last accessed 26 January 2011]
105. FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer. Bethesda, MD: clinicaltrials.gov, 2010. Available from: [Last accessed 26 January 2011]
106. Huang TF, Sheu JR, Teng CM, et al. Triflavin, an antiplatelet Arg-Gly-Asp-containing peptide, is a specific antagonist of platelet membrane glycoprotein Iib-IIIa complex. J Biochem 1991;109:328-34
107. Sheu JR, Lin CH, Chung JL, et al. Triflavin, an Arg-Gly-Asp-containing antiplatelet peptide inhibits cell-substratum adhesion and melanoma cell-induced lung colonization. Jpn J Cancer Res 1992;83:885-93
108. Sheu JR, Lin CH, Huang TF. Triflavin, an antiplatelet peptide, inhibits tumor cell-extracellular matrix adhesion through an arginine-glycine-aspartic acid-dependent mechanism. J Lab Clin Med 1994;123:256-63
109. Sheu JR, Lin CH, Peng HC, Huang TF. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells. Proc Soc Exp Biol Med 1996;213:71-9
110. Wu ZZ, Li P, Huang QP, et al. Inhibition of adhesion of hepatocellular carcinoma cells to basement membranecomponents by receptor competition with RGD- or YIGSR-containing synthetic peptides. Biorheology 2003;40:489-502 (Pubitemid 36693675)
111. Qian J, Yin J, Liang H, et al. Experimental study on transarterial administration of GRGDSP combined with transarterial chemoembolization in rats with hepatic carcinoma. Cardiovasc Intervent Radiol 2008;31:377-82
112. Fujii H, Nishikawa N, Komazawa H, et al. A new pseudo-peptide of Arg-Gly-Asp (RGD) with inhibitory effect on tumor metastasis and enzymatic degradation of extracellular matrix. Clin Exp Metastasis 1998;16:94-104 (Pubitemid 28122559)
113. Ohnishi Y, Fujii H, Murakami K, et al.A new pseudo-peptide analogue of the Arg-Gly-Asp (RGD) sequence inhibits liver metastasis of colon 26-L5 carcinoma cells. Cancer Lett 1998;124:157-63 (Pubitemid 28073682)
114. Tsuchiya Y, Sawada S, Tsukada K, Saiki I. A new pseudo-peptide of Arg-Gly-Asp (RGD) inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Int J Oncol 2002;20:319-24
115. Zhang GM, Yang Y, Huang B, et al. Experimental study on therapeutic effect of in vivo expression of Cell I-Hep II recombinant polypeptide of fibronectin on murine H22 hepatocellular carcinoma. World J Gastroenterol 2003;9:1940-5 (Pubitemid 37168417)
116. Liu Y, Huang B, Yuan Y, et al. Inhibition of hepatocarcinoma and tumor metastasis to liver by gene therapy with recombinant CBD-HepII polypeptide of fibronectin. Int J Cancer 2007;121:184-92 (Pubitemid 46753867)
117. Gong W, Liu Y, Huang B, et al. Recombinant CBD-HepII polypeptide of fibronectin inhibits alphavbeta3 signaling and hematogenous metastasis of tumor. Biochem Biophys Res Commun 2008;367:144-9
118. Sudhakar A, Sugimoto H, Yang C, et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alphavbeta3 and alpha5beta1 integrins. Proc Natl Acad Sci USA 2003;100:4766-71 (Pubitemid 36457804)
119. Maeshima Y, Colorado PC, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275:21340-8 (Pubitemid 30481833)
120. Goto T, Ishikawa H, Matsumoto K, et al. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis. Int J Oncol 2008;33:33-40
121. Hansma AH, Broxterman HJ, van der Horst I, et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol 2005;16:1695-701 (Pubitemid 41510146)
122. Eder JP Jr, Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772-84
123. Second-line therapy study of combined chemotherapy and endostar to patients with Non-Small Cell Lung Cancer (NSCLC). Bethesda, MD: clinicaltrials. gov, 2008. Available from: [Last accessed 26 January 2011]
124. Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer. Bethesda, MD: clinicaltrials.gov, 2009. Available from: [Last accessed 26 January 2011]
125. Synergistic treatment for Hepatocellular Carcinoma (HCC) using TACE with Antiangiogenesis (TACE HCC) Bethesda, MD: clinicaltrials.gov, 2007. Available from: [Last accessed 26 January 2011]
126. Li J, Tan H, Dong X, et al. Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig Liver Dis 2007;39:557-65 (Pubitemid 46746642)
127. Liu Z, Wang J, Yin P, et al. RGD-FasL induces apoptosis in hepatocellular carcinoma. Cell Mol Immunol 2009;6:285-93
128. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alphavbeta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64
129. Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis 1992;10:111-20
130. Li X, Regezi J, Ross FP, et al. Integrin alphavbeta3 mediates K1735 murine melanoma cell motility in vivo and in vitro. J Cell Sci 2001;114:2665-72 (Pubitemid 32734414)
131. Zheng DQ, Woodard AS, Fornaro M, et al. Prostatic carcinoma cell migration via alphavbeta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999;59:1655-64 (Pubitemid 29160140)
132. Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: association of the beta3 subunit with tumor progression. Cancer Res 1990;50:6757-64 (Pubitemid 20348810)
133. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin alphavbeta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4:2625-34 (Pubitemid 28523488)
134. Weinel RJ, Rosendahl A, Neumann K, et al. Expression and function of VLA-alpha2, -alpha3, -alpha5 and -alpha6-integrin receptors in pancreatic carcinoma. Int J Cancer 1992;52:827-33
135. Cress AE, Rabinovitz I, Zhu W, Nagle RB. The alpha6beta1 and alpha6beta4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995;14:219-28
136. Stallmach A, von Lampe B, Matthes H, et al. Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation. Gut 1992;33:342-46
137. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009;15:392-400
138. Alghisi GC, Ponsonnet L, Ruegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 2009;4:e4449:published online 12 February 2009, doi:10.1371/journal. pone.0004449
139. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9
140. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
141. Sroka TC, Pennington ME, Cress AE. Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5. Carcinogenesis 2006;27:1748-57 (Pubitemid 44288658)
142. DeRoock IB, Pennington ME, Sroka TC, et al. Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins. Cancer Res 2001;61:3308-13 (Pubitemid 32695018)
143. Eble JA, Bruckner P, Mayer U. Vipera lebetina venom contains two disintegrins inhibiting laminin-bindingbeta1 integrins. J Biol Chem 2003;278:26488-96 (Pubitemid 36876790)
144. Iwamoto Y, Robey FA, Graf J, et al. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987;238:1132-4 (Pubitemid 18011956)
145. Sakamoto N, Iwahana M, Tanaka NG, Osada Y. Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res 1991;51:903-6
146. Nakai M, Mundy GR, Williams PJ, et al. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 1992;52:5395-9
147. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alphavbeta3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991;88:1924-32
148. A pilot study of adjuvant therapy of gefitinib (Iressa, ZD1839) in patients with Resectable Hepatocellular Carcinoma. Bethesda, MD: clinicaltrials. gov, 2006. Available from: [Last accessed 26 January 2011]
149. Giannelli G, Azzariti A, Fransvea E, et al. Laminin-5 offsets the efficacy of gefitinib (Iressa) in hepatocellular carcinoma cells. Br J Cancer 2004;91:1964-9 (Pubitemid 40065526)
150. Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008;47:1557-66 (Pubitemid 351702739)
151. Zhang B, Halder SK, Zhang S, Datta PK. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 2009;277:114-20
152. Xu Y, Tabe Y, Jin L, et al. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 2008;142:192-201 (Pubitemid 351987311)